OPKO Health Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 OPKO Health Inc 公司

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

OPKO Health Inc简介



公司代码OPK

公司名称OPKO Health Inc

上市日期Nov 02, 1995

CEOCruz (Tony F)

员工数量2997

证券类型Ordinary Share

年结日Nov 02

公司地址- -

城市- -

上市交易所NASDAQ OMX - NASDAQ BASIC

国家- -

邮编- -

电话- -

网址- -

公司代码OPK

上市日期Nov 02, 1995

CEOCruz (Tony F)

OPKO Health Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Adam E. Logal

Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer

179.16K

--

Dr. Richard M. Krasno, Ph.D.

Independent Director

103.33K

--

Dr. Elias A. Zerhouni, M.D.

President, Vice Chairman of the Board

89.60K

--

Dr. Alice Lin-Tsing Yu, M.D., Ph.D.

Independent Director

66.49K

--

Mr. John A. Paganelli

Independent Director

--

Dr. Phillip Frost ,M.D.

Chairman of the Board, Chief Executive Officer

--

Dr. Jane H. Hsiao, Ph.D.

Vice Chairman of the Board, Chief Technical Officer

--

Mr. Steven D. (Steve) Rubin, Esq., J.D.

Executive Vice President - Administration, Director

--

Mr. Richard C. (Rick) Pfenniger, Jr.

Independent Director

--

Dr. Charles W. Bishop, Ph.D.

Chief Executive Officer of OPKO Renal

--

名称

名称/职务

职务

持股

持股变动

Mr. Adam E. Logal

Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer

179.16K

--

Dr. Richard M. Krasno, Ph.D.

Independent Director

103.33K

--

Dr. Elias A. Zerhouni, M.D.

President, Vice Chairman of the Board

89.60K

--

Dr. Alice Lin-Tsing Yu, M.D., Ph.D.

Independent Director

66.49K

--

Mr. John A. Paganelli

Independent Director

--

Dr. Phillip Frost ,M.D.

Chairman of the Board, Chief Executive Officer

--

收入明细

单位: USD更新时间: 4月6日周一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Health Insurers

213.60M

57.69%

Client Payers

87.61M

23.66%

Government Payers

59.92M

16.18%

Patients

9.14M

2.47%

地区USD

名称

营收

占比

United States

436.06M

71.85%

Chile

62.38M

16.85%

Ireland

51.40M

13.88%

Spain

26.73M

7.22%

Mexico

25.52M

6.89%

其他

-231.81M

-16.69%

业务

地区

业务USD

名称

营收

占比

Health Insurers

213.60M

57.69%

Client Payers

87.61M

23.66%

Government Payers

59.92M

16.18%

Patients

9.14M

2.47%

股东统计

更新时间: 5月10日周日

持股股东

股东类型

持股股东

占比

Frost Gamma Investments Trust

28.70%

Rubric Capital Management LP

6.33%

Holbrook (Bruce C)

5.35%

Hsiao (Jane H)

4.39%

Frost Group, L.L.C.

4.31%

其他

50.93%

持股股东

占比

Frost Gamma Investments Trust

28.70%

Rubric Capital Management LP

6.33%

Holbrook (Bruce C)

5.35%

Hsiao (Jane H)

4.39%

Frost Group, L.L.C.

4.31%

其他

50.93%

股东类型

持股股东

占比

Corporation

38.33%

Investment Advisor

12.75%

Individual Investor

11.15%

Hedge Fund

7.72%

Investment Advisor/Hedge Fund

5.59%

Research Firm

0.64%

Bank and Trust

0.24%

Pension Fund

0.13%

Venture Capital

0.05%

其他

23.40%

机构持股



更新时间: 4月1日周三

报告期

机构数

持股数

持股占比

持股变动

2026Q1

451

236.82M

31.36%

-9.38M

2025Q4

453

195.81M

25.51%

-55.48M

2025Q3

457

208.31M

27.13%

-63.18M

2025Q2

472

618.23M

77.88%

-578.48K

2025Q1

498

645.32M

88.41%

+25.74M

2024Q4

501

573.04M

84.80%

-7.63M

2024Q3

497

562.18M

81.01%

-12.00M

2024Q2

501

553.77M

79.70%

+8.59M

2024Q1

492

531.83M

76.52%

-21.84M

2023Q4

493

533.01M

69.65%

+31.42M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Frost Gamma Investments Trust

222.46M

29.31%

+2.15M

+0.98%

Nov 21, 2025

Rubric Capital Management LP

47.79M

6.3%

--

Dec 31, 2025

Holbrook (Bruce C)

40.38M

5.32%

--

Feb 24, 2025

Hsiao (Jane H)

33.13M

4.36%

--

Apr 02, 2025

Frost Group, L.L.C.

30.13M

3.97%

--

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

31.23M

4.11%

+1.54M

+5.20%

Dec 31, 2025

GJN 2021 Trust

19.91M

2.62%

--

Feb 24, 2025

EGN 2021 Trust

19.91M

2.62%

--

Feb 24, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

Invesco NASDAQ Future Gen 200 ETF

0.53%

State Street SPDR S&P Health Care Services ETF

0.46%

VanEck Israel ETF

0.14%

Humankind US Stock ETF

0.1%

iShares U.S. Healthcare Providers ETF

0.1%

Goldman Sachs Innovate Equity ETF

0.06%

iShares MSCI USA Small-Cap Min Vol Factor ETF

0.05%

iShares Russell 2000 Value ETF

0.04%

iShares Biotechnology ETF

0.04%

Invesco RAFI US 1500 Small-Mid ETF

0.04%

Invesco NASDAQ Future Gen 200 ETF

占比0.53%

State Street SPDR S&P Health Care Services ETF

占比0.46%

VanEck Israel ETF

占比0.14%

Humankind US Stock ETF

占比0.1%

iShares U.S. Healthcare Providers ETF

占比0.1%

Goldman Sachs Innovate Equity ETF

占比0.06%

iShares MSCI USA Small-Cap Min Vol Factor ETF

占比0.05%

iShares Russell 2000 Value ETF

占比0.04%

iShares Biotechnology ETF

占比0.04%

Invesco RAFI US 1500 Small-Mid ETF

占比0.04%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据